Company intelligence / Profile preview

LumeRx

Austin, Texas, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~900
Development stage: Other

Overview

Luminex developed and commercialized multiplexing technologies such as xMAP and MultiCode that enable simultaneous detection of up to 500 analytes from a single sample. These platforms are widely used in clinical diagnostics, drug discovery, genetic analysis, food safety testing, and biomedical research. The company’s products have been implemented globally with over 7,000 instruments shipped. Notable recent results include enabling new blood tests for Alzheimer’s disease biomarkers.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: DeviceDiagnostic assayMultiplexed immunoassayPCR-based assay
Industry: Molecular Diagnostics

Partnerships

Bio-Rad LaboratoriesInvitrogen/Thermo Fisher Scientific ProcartaPlex assaysMilliporeSigma/Merck KGaA R&D Systems

Beyond the preview

Go deeper on LumeRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LumeRx.

Explore the full profile